Faustinus Onyirimba, MD
Pulmonary Disease · Vernon, CTNPI 1831145549
Payments from drug & device makers
Across 527 payments — averaging $21.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$3K
- AstraZeneca$2K
- Regeneron Healthcare Solutions, Inc.$690
- Takeda Pharmaceuticals U.S.A., Inc.$590
- Amgen$571
- Actelion Pharmaceuticals US, Inc.$536
- plus $4K from 30 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 210 | $3,291 |
| AstraZeneca | 73 | $1,816 |
| Regeneron Healthcare Solutions, Inc. | 23 | $690 |
| Takeda Pharmaceuticals U.S.A., Inc. | 20 | $590 |
| Amgen | 23 | $571 |
| Actelion Pharmaceuticals US, Inc. | 15 | $536 |
| Sanofi | 28 | $534 |
| Boehringer Ingelheim | 18 | $510 |
| Mallinckrodt Hospital Products Inc. | 11 | $432 |
| Genentech USA, Inc. | 18 | $335 |
| Pfizer | 11 | $263 |
| Insmed, Inc. | 7 | $210 |
| Novartis | 17 | $197 |
| Johnson & Johnson(2 entities) | 8 | $197 |
| Verona Pharma, Inc. | 6 | $159 |
| Sanofi-aventis U.S. LLC | 2 | $145 |
| Grifols USA, LLC | 4 | $118 |
| Merck | 3 | $88 |
| Inspire Medical Systems, Inc. | 3 | $80 |
| Ambu Inc. | 4 | $65 |
| Covis Pharma GmbH | 3 | $63 |
| Baxter Healthcare | 2 | $57 |
| Philips North America LLC | 3 | $55 |
| Viatris Specialty LLC | 2 | $53 |
| Inogen, Inc. | 2 | $40 |
| AbbVie | 1 | $31 |
| Alk-abello, Inc | 1 | $30 |
| Jazz Pharmaceuticals Inc. | 1 | $30 |
| Harmony Biosciences LLC | 1 | $28 |
| Lilly USA, LLC | 1 | $28 |
| Optinose US, Inc. | 1 | $24 |
| Pulmonx Corporation | 1 | $24 |
| Electromed, Inc. | 1 | $22 |
| CSL Behring | 1 | $22 |
| Sunovion Pharmaceuticals Inc. | 1 | $16 |
| Teva Pharmaceuticals USA, Inc. | 1 | $12 |
How this compares
$11,366 in reported general payments places this provider in the 75th percentile of 255 pulmonary disease providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other pulmonary disease in Vernon
- Geoffrey ChuppNew Haven$3.1M
- Jonathan KoffNew Haven$1.1M
- Naftali KaminskiNew Haven$1M
- Danielle Antin-OzerkisNew Haven$1M
- Mircea BadaraNew Britain$1M
- Mridu GulatiNew Haven$536K
- Phillip JosephNew Haven$488K
- Tapas BandyopadhyayWest Hartford$483K
- Raj ParikhHartford$419K
- Patrick TroyHartford$385K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.